In plain terms: Chromium (Picolinate) shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
Chromium (Picolinate)
The evidence as the record states it
Suksomboon et al. (Journal of Clinical Pharmacy and Therapeutics, 2014; PMID 24635480): meta-analysis of 25 randomized trials, 22 of chromium alone; HbA1c fell 0.55 percentage points (95% CI 0.22 to 0.88) and fasting glucose 1.15 mmol/L; the effect concentrated in chromium picolinate, doses above 200 mcg/day and patients with poor baseline control. Asbaghi et al. (Pharmacol Res, 2020; PMID 32730903): meta-analysis of 28 studies in type 2 diabetes; HbA1c fell 0.71 points (95% CI 0.23 to 1.19), with extreme heterogeneity on fasting glucose (I-squared 99.8 percent). Yin and Phung (Nutr J, 2015; PMID 25971249): meta-analysis of 14 randomized trials analyzed by chromium form; chromium picolinate, chromium yeast and brewer's yeast showed no significant effect on HbA1c. Grade C: a pooled glycemic signal in two meta-analyses that a third, analyzing picolinate on its own, did not find.
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.